BlackRock
SGP

BlackRock’s SpyGlass Pharma SGP Stock Holding History

BlackRock’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Buy
711,712
+566,973
+392% +$12.3M ﹤0.01% 3415
2026
Q1 		$3.75M Buy
+144,739
New +$3.89M ﹤0.01% 3939

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's SGP Position: Q2 2026 in Review

BlackRock increased its SpyGlass Pharma (SGP) stake by 392% in Q2 2026, buying an estimated $12.3M and bringing the position to 711,712 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3415.

BlackRock first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • BlackRock held 711,712 shares of SpyGlass Pharma worth $15.8M as of Q2 2026.
  • BlackRock bought 566,973 SpyGlass Pharma shares in Q2 2026, an estimated $12.3M.
  • SpyGlass Pharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3415 holding.
  • BlackRock first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.